Clinical Trials

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of EVEROLIMUS in Patients with High-Risk, Hormone Receptor-Positive AND HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy Marion L. Shepard Cancer Center

Disease/Site: Breast
Protocol Number: SWOG S1207 (e3)
Phase: III

PI/Coordinator: John Inzerillo/ Kristy Alligood
Open Date:
Contact Information: 252-974-9390/252-974-9389

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer Marion L. Shepard Cancer Center

Disease/Site: Breast
Protocol Number: NRG-BR003
Phase: III

PI/Coordinator: John Inzerillo/ Kristy Alligood
Open Date:
Contact Information: 252-974-9389/252-974-9391

A Randoized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Stage Breast Cancer Marion L. Shepard Cancer Center

Disease/Site: Breast
Protocol Number: Alliance A011401 (BWEL)
Phase: III

PI/Coordinator: John Inzerillo/ Kristy Alligood
Open Date:
Contact Information: 252-974-9389/252-974-9392

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer Marion L. Shepard Cancer Center

Disease/Site: Breast
Protocol Number: Alliance A011502 (ABC Trial)
Phase: III

PI/Coordinator: John Inzerillo/ Kristy Alligood
Open Date:
Contact Information: 252-974-9389/252-974-9393

Testing the Effect of Aspirin on Breast Density: A companion study to Alliance Study A011502 Marion L. Shepard Cancer Center

Disease/Site: Breast (PND IRB APP)
Protocol Number: A211601
Phase:

PI/Coordinator: John Inzerillo/ Kristy Alligood
Open Date:
Contact Information: 252-974-9389/252-974-9394

A Phase II Trial Assessing the tolerability of Palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor positive, HER-2 negative metastatic breast cancer Marion L. Shepard Cancer Center

Disease/Site: Breast (PND IRB APP)
Protocol Number: A171601
Phase: II

PI/Coordinator: John Inzerillo/ Kristy Alligood
Open Date:
Contact Information: 252-974-9389/252-974-9395

A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 Marion L. Shepard Cancer Center

Disease/Site: CLL
Protocol Number: TG Therapeutics UTX-TGR 204 (UNITY - CLL)
Phase: III

PI/Coordinator: "John Inzerillo/ Kristy Alligood "
Open Date:
Contact Information: 252-974-9389/252-974-9404

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) Marion L. Shepard Cancer Center

Disease/Site: Colorectal (PND IRB APP)
Protocol Number: SWOG S0820 (PACES)
Phase: III

PI/Coordinator: John Inzerillo/ Kristy Alligood
Open Date:
Contact Information: 252-974-9389/252-974-9401

Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas Marion L. Shepard Cancer Center

Disease/Site: Gastroenteropancreatic
Protocol Number: ECOG-ACRIN EA2142
Phase: II

PI/Coordinator: John Inzerillo/ Kristy Alligood
Open Date:
Contact Information: 252-974-9389/252-974-9400

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST – Genotype Screening component) Marion L. Shepard Cancer Center

Disease/Site: Lung
Protocol Number: Alliance A151216 (ALCHEMIST)
Phase: NA

PI/Coordinator: John Inzerillo/ Kristy Alligood
Open Date:
Contact Information: 252-974-9389/252-974-9396

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completed Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) Marion L. Shepard Cancer Center

Disease/Site: Lung
Protocol Number: Alliance A081105 (ALCHEMIST)
Phase: III

PI/Coordinator: John Inzerillo/ Kristy Alligood
Open Date:
Contact Information: 252-974-9389/252-974-9397

A Phase III Double blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein Marion L. Shepard Cancer Center

Disease/Site: Lung
Protocol Number: ECOG-ACRIN E4512 (ALCHEMIST)
Phase: III

PI/Coordinator: John Inzerillo/ Kristy Alligood
Open Date:
Contact Information: 252-974-9389/252-974-9398

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL): A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers Marion L. Shepard Cancer Center

Disease/Site: Lung
Protocol Number: ECOG-ACRIN EA5142 (ALCHEMIST)
Phase: III

PI/Coordinator: John Inzerillo/ Kristy Alligood
Open Date:
Contact Information: 252-974-9389/252-974-9399

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma Marion L. Shepard Cancer Center

Disease/Site: Lymphoma
Protocol Number: TG Therapeutics UTX-TGR 205 (UNITY - NHL)
Phase: IIb

PI/Coordinator: John Inzerillo/ Kristy Alligood
Open Date:
Contact Information: 252-974-9389/252-974-9405

A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States Marion L. Shepard Cancer Center

Disease/Site: Prostate
Protocol Number: Astellas ONC-MA-1004 (TRUMPET)
Phase: NA

PI/Coordinator: John Inzerillo/ Kristy Alligood
Open Date:
Contact Information: 252-974-9389/252-974-9402

Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial Marion L. Shepard Cancer Center

Disease/Site: Prostate (PND IRB APP)
Protocol Number: ECOG-ACRIN EA8153 (CHAARTED2)
Phase:

PI/Coordinator: John Inzerillo/ Kristy Alligood
Open Date:
Contact Information: 252-974-9389/252-974-9403

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors Marion L. Shepard Cancer Center

Disease/Site: Solid Tumors (PND IRB APP)
Protocol Number: Exact Sciences 2018-01
Phase:

PI/Coordinator: John Inzerillo/ Kristy Alligood
Open Date:
Contact Information: 252-974-9389/252-974-9406

Collection and Distribution of Remnant and Research Use Only Biospecimens for Novel Research Uses Marion L. Shepard Cancer Center

Disease/Site: Solid Tumors (PND IRB APP)
Protocol Number: iSpecimen ISPC-180630
Phase:

PI/Coordinator: John Inzerillo/ Kristy Alligood
Open Date:
Contact Information: 252-974-9389/252-974-9407

A Phase II, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: AIHA
Protocol Number: C-935788-053
Phase: II

PI/Coordinator: Liles/Amanda Wetherington
Open Date:
Contact Information: 252-744-5687

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: AL Amloidosis
Protocol Number:
Phase: II

PI/Coordinator: Liles/Denise Brigham
Open Date:
Contact Information: 252-744-4924

AFT-39: Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the ""PRO-TECT"" trial) Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: All Sites
Protocol Number: AFT-39 PRO-TECT
Phase: NA

PI/Coordinator: Muzaffar/ Amanda Wetherington
Open Date:
Contact Information: 252-744-5687

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation. Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: AML
Protocol Number: AGIOS AG120-C-009 (AGILE)
Phase: III

PI/Coordinator: Liles/ Denise Brigham
Open Date:
Contact Information: 252-744-4924

A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with newly Diagnosed High-Risk AML Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: AML
Protocol Number: Tolero TPI0ALV-201
Phase: III

PI/Coordinator: Liles/ Denise Brigham
Open Date:
Contact Information: 252-744-4924

The Myelodysplastic Syndromes (MDS) and AML Registry Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: AML & MDS
Protocol Number: Connect
Phase: NA

PI/Coordinator: Liles/ Denise Brigham
Open Date:
Contact Information: 252-744-4924

A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older (LEAP: Intergroup Less Intense AML Platform Trial) Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: AML & MDS
Protocol Number: SWOG S1612
Phase: II/III

PI/Coordinator: Liles/ Denise Brigham
Open Date:
Contact Information: 252-744-4924

A study looking at targeted therapy accoridng to tumor markers for people with meningiomas: Phase II Trial of SMO/AKT/NF2 inhibitors in progressive meningiomas with SMO/AKT/NF2 mutations Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Brain
Protocol Number: Alliance A071401 (Temp CTA as of 2/8/18)
Phase: II

PI/Coordinator: Lepera/ Renee Coghill
Open Date:
Contact Information: 252-744-5723

Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + PLacebo (BeSt) For Radionecrosis After Radiosurgery for Brain Mestastases Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Brain
Protocol Number: Alliance A221208
Phase: III

PI/Coordinator: Lepera/ Renee Coghill
Open Date:
Contact Information: 252-744-5723

Alternate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a Phase III Study Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Breast
Protocol Number: Alliance A011106 (ALTERNATE) (Temp CTA as of 11/1/18)
Phase: III

PI/Coordinator: Muzaffar/ Renee Coghill
Open Date:
Contact Information: 252-744-5723

A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Position Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Breast
Protocol Number: Alliance A011202
Phase: III

PI/Coordinator: Muzaffar/ Renee Coghill
Open Date:
Contact Information: 252-744-5723

Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs Placebo in Combination With Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Breast
Protocol Number: ONT-380-206 (HER2CLIMB)
Phase: II

PI/Coordinator: Muzaffar/ Renee Coghill
Open Date:
Contact Information: 252-744-5723

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Breast
Protocol Number: NRG-BR003
Phase: III

PI/Coordinator: Muzaffar/ Renee Coghill
Open Date:
Contact Information: 252-744-5723

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Breast
Protocol Number: NSABP B-51
Phase: III

PI/Coordinator: Muzaffar/ Renee Coghill
Open Date:
Contact Information: 252-744-5723

AFT-25-Comparison of Operative To Monitoring And Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Breast
Protocol Number: AFT-25 COMET
Phase: III

PI/Coordinator: Wong/ Renee Coghill
Open Date:
Contact Information: 252-744-5723

Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Breast
Protocol Number: POLARIS
Phase:

PI/Coordinator: Muzaffar/ Renee Coghill
Open Date:
Contact Information: 252-744-5723

A Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of BIVV009 in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: CAgD
Protocol Number: Cardinal BIVV009-03
Phase: NA

PI/Coordinator: Liles/ Amanda Wetherington
Open Date:
Contact Information: 252-744-5687

A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of BIVV009 in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: CAgD
Protocol Number: Cadenza BIVV009-04
Phase: NA

PI/Coordinator: Liles/ Bolaji Babatunde
Open Date:
Contact Information: 252-744-0320

Carolina Senior: UNC Registry For Older Patients Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Cancer Registry
Protocol Number: LCCC0916
Phase: NA

PI/Coordinator: Walker/Any Available
Open Date:
Contact Information: 252-744-0456

A Disease Registry for Patients with Chronic Lymphocytic Leukemia Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: CLL
Protocol Number: informCLL
Phase:

PI/Coordinator: Liles/ Bolaji Babatunde
Open Date:
Contact Information: 252-744-0320

A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects with Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Essential Thrombocytopenia
Protocol Number: INCB 18424-272 (RESET)
Phase: II

PI/Coordinator: Liles/ Tiffanie Moore
Open Date:
Contact Information: 252-744-1720

PIPER: A Prospective, Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Hematology/Oncology
Protocol Number: PIPER
Phase: IV

PI/Coordinator: Liles/ Kaitlyn Walker
Open Date:
Contact Information: 252-744-0456

AFT-28: Direct Oral Anticoagulants (DOACS) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial) Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Hematology/Oncology
Protocol Number: CANVAS
Phase:

PI/Coordinator: Liles/ Renee Coghill
Open Date:
Contact Information: 252-744-5723

AFT-28: Direct Oral Anticoagulants (DOACS) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial) Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Hematology/Oncology
Protocol Number: CANVAS
Phase:

PI/Coordinator: Liles/ Renee Coghill
Open Date:
Contact Information: 252-744-5723

INCB-MA-MF-401 (MOST): Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Low-Risk MF or High-Risk ET
Protocol Number: INCB-MA-MF-401 (MOST)
Phase: NA

PI/Coordinator: Liles/ Tiffanie Moore
Open Date:
Contact Information: 252-744-1720

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST – Genotype Screening component) Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Lung
Protocol Number: Alliance A151216 (ALCHEMIST)
Phase: NA

PI/Coordinator: Walker/ Susan Eubanks
Open Date:
Contact Information: 252-744-1015

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completed Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Lung
Protocol Number: Alliance A081105 (ALCHEMIST)
Phase: II

PI/Coordinator: Walker/ Susan Eubanks
Open Date:
Contact Information: 252-744-1015

Smoking Cessation Prior to Surgery to Reduce Surgical Complications Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Lung
Protocol Number: Alliance A211401
Phase: III

PI/Coordinator: Speicher/ Susan EubanksS
Open Date:
Contact Information: 252-744-1015

A Phase III Double blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Lung
Protocol Number: ECOG-ACRIN E4512 (ALCHEMIST)
Phase: III

PI/Coordinator: Walker/ Susan Eubanks
Open Date:
Contact Information: 252-744-1015

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville

Disease/Site: Lung
Protocol Number: ECOG-ACRIN EA5142
Phase: III

PI/Coordinator: "Walker/ Susan Eubanks
Open Date:
Contact Information: 252-744-1015

"Phase II trial regarding the effect of comprehensive symptom management on inflammation and survival in metastatic lung cancer Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Lung
Protocol Number: INSYNC
Phase:

PI/Coordinator: "Stroud/ Susan Eubanks"
Open Date:
Contact Information: 252-744-1015

"Predictive value of the modified glasgow prognostic score among patients undergoing immunotherapy with PD-1 targeted agents Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Lung
Protocol Number: P-MAIT
Phase: NA

PI/Coordinator: "Walker/ Amanda Wetherington"
Open Date:
Contact Information: 252-744-5687

"SNAP: Prognostic Value of the Modified Glasgow Prognostic Score In A North American Population of Thoracic Oncology Patients Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Lung
Protocol Number: SNAP
Phase: NA

PI/Coordinator: "Walker/ Amanda Wetherington"
Open Date:
Contact Information: 252-744-5687

"BDX-00146: An Observational Study Assessing the Clinical Effectiveness of VeriStrat® and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Lung
Protocol Number: BDX-00146
Phase:

PI/Coordinator: "Walker/ Kaitlyn Walker"
Open Date:
Contact Information: 252-744-0456

"Trends of Circulating Tumor DNA Levels in Patients Treated with Immune Therapy Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Lung
Protocol Number: CLIP-IT
Phase: NA

PI/Coordinator: "Yogarajah/ Amanda Wetherington"
Open Date:
Contact Information: 252-744-5687

"Identification of Biomarkers in Lung Cancer Patients Treated with Immunotherapy Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Lung
Protocol Number: Yang
Phase: NA

PI/Coordinator: "Stroud/ Susan Eubanks"
Open Date:
Contact Information: 252-744-1015

"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU) Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Lung
Protocol Number: "Abbvie M16-298"
Phase:

PI/Coordinator: "Walker/ Amanda Wetherington"
Open Date:
Contact Information: 252-744-5687

"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU) Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Lung
Protocol Number: "Abbvie M16-298"
Phase:

PI/Coordinator: "Walker/ Amanda Wetherington"
Open Date:
Contact Information: 252-744-5687

"Biomarkers of Immunotherapy Related Thromboembolic Events Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Lung
Protocol Number: Aparna Hedge Research Fellowship
Phase: NA

PI/Coordinator: Walker (Hegde)/ Amanda Wetherington
Open Date:
Contact Information: 252-744-5687

"OP-103 OCEAN: A Randomized, Controlled,Open-Label, Phase 3 Study of Melflufen/Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Multiple Myeloma
Protocol Number: OP-103 OCEAN
Phase: III

PI/Coordinator: "Liles/ Denise Brigham"
Open Date:
Contact Information: 252-744-4924

"A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Multiple Myeloma
Protocol Number: Alliance A061202
Phase: II

PI/Coordinator: "Liles/ Denise Brigham"
Open Date:
Contact Information: 252-744-4924

"Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Multiple Myeloma
Protocol Number: ECOG-ACRIN E1A11
Phase: III

PI/Coordinator: "Liles/ Denise Brigham"
Open Date:
Contact Information: 252-744-4924

"Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 812) Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: NHL
Protocol Number: "BMS CA209-812"
Phase: III

PI/Coordinator: "Liles/ Denise Brigham"
Open Date:
Contact Information: 252-744-4924

"Trans(Intra)-arterial Gemcitabine vs. Continuation of IV Gemcitabine and Nab-Paclitaxel following Radiotherapy for Locally Advanced Pancreatic Cancer Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Pancreas
Protocol Number: Renovo TIGeR-PaC
Phase:

PI/Coordinator: "Zervos/ Kaitlyn Walker"
Open Date:
Contact Information:

"Feasibility trial for treatment of resectable pancreatic cancer with the permanently implantable LDR CivaSheet Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Pancreas
Protocol Number: "CivaTech CT005 (Temp CTA by PI until protocol amendment)"
Phase: II

PI/Coordinator: "Zervos/Ju/ Amanda Wetherington"
Open Date:
Contact Information: 252-744-5687

"Preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Pancreas
Protocol Number: Alliance A021501 (Temp CTA as of 5/9/18)
Phase:

PI/Coordinator: "Muzaffar/ Renee Coghill"
Open Date:
Contact Information: 252-744-5723

"A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Rectal
Protocol Number: Alliance N0148 (Prospect)
Phase: II/III

PI/Coordinator: "Walker/ Renee Coghill"
Open Date:
Contact Information: 252-744-5723

"A phase 2, Muticenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Sickle Cell
Protocol Number: Novartis CSEG10A2202
Phase: III

PI/Coordinator: "Liles/ Kaitlyn Walker"
Open Date:
Contact Information: 252-744-0456

"A Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Rivipansel (GMI-1070) in the treatment of vaso-occlusive crisis in hospitalized subjects with sickle cell disease Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Sickle Cell
Protocol Number: B5201002
Phase: III

PI/Coordinator: "Liles/ Denise Brigham"
Open Date:
Contact Information: 252-744-4924

"An Open-Label Extension Study to Evaluate the Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects with Sickle Cell Disease Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Sickle Cell
Protocol Number: B5201003
Phase: III

PI/Coordinator: "Liles/ Denise Brigham"
Open Date:
Contact Information: 252-744-4924

"A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease. Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Sickle Cell
Protocol Number: "GBT440-031 HOPE (on hold for data analysis)"
Phase: III

PI/Coordinator: "Liles/ Kaitlyn Walker"
Open Date:
Contact Information: 252-744-0456

"A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia) Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Sickle Cell
Protocol Number: Imara IMR-SCD-102
Phase: II

PI/Coordinator: "Liles/ Kaitlyn Walker"
Open Date:
Contact Information: 252-744-0456

"A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: Sickle Cell
Protocol Number: Ironwood C1701-202
Phase: II

PI/Coordinator: "Liles/ Kaitlyn Walker"
Open Date:
Contact Information: 252-744-0456

"United States Thrombotic Microangiopathy (USTMA) Thrombotic Thrombocytopenic Purpura (TTP) Clinical Data and Biologic Sample Repository Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: TTP
Protocol Number: USTMA TTP
Phase: NA

PI/Coordinator: "Liles/ Tiffanie Moore"
Open Date:
Contact Information: 252-744-1720

"Thrombotic Thrombocytopenic Purpura (TTP) Registry Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: TTP Registry
Protocol Number: TTP Registry
Phase: NA

PI/Coordinator: "Liles/ Any Available"
Open Date:
Contact Information: 252-744-0456

"Studying Interventions for Managing Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY) Vidant Cancer Care at the Eddie and Jo Allison Smith Tower in Greenville"

Disease/Site: VML
Protocol Number: "BMS CA-180-653"
Phase:

PI/Coordinator: "Liles/ Bolaji Babatunde"
Open Date:
Contact Information: 252-744-0320

"A phase II study of blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for patients ≥ 65 years of age with newly diagnosed Philadelphia-chromosome negative (PH-) acute lymphoblastic leukemia (ALL) and of dasatinib, prednisone and blinatumomab for patients ≥ 65 years of age with newly diagnosed Philadelphia-chromosone positive (PH+) ALL Vidant Oncology-Kinston"

Disease/Site: ALL
Protocol Number: SWOG S1318
Phase: II

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"Phase III randomized trial of clofarabine as induction and post-remission therapy vs. standard daunorubicin & cytarabine induction and intermediate dose cytarabine post-remission therapy, followed by decitabine maintenance vs. observation in newly-diagnosed acute myeloid leukemia in older adults (age ≥ 60 years) Vidant Oncology-Kinston"

Disease/Site: AML
Protocol Number: ECOG E2906
Phase: III

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"The Myelodysplastic Syndromes (MDS) and AML Registry Vidant Oncology-Kinston"

Disease/Site: AML & MDS
Protocol Number: Connect
Phase: NA

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A phase III randomized, double-blind placebo controlled study of Armodafinil (Nuvigil) to reduce cancer-related fatigue in patients with high grade glioma Vidant Oncology-Kinston"

Disease/Site: Brain
Protocol Number: "Alliance A221101"
Phase: II

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A phase II/III randomized trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma with MGMT promoter hypermethylation Vidant Oncology-Kinston"

Disease/Site: Brain
Protocol Number: Alliance A071102
Phase: II/III

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A phase III study Vidant Oncology-Kinston"

Disease/Site: Breast
Protocol Number: Alliance A011106
Phase: III

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A randomized phase III post-operative trial of platinum based chemotherapy vs. observation in patients with residual triple-negative basal-like breast cancer following neoadjuvant chemotherapy Vidant Oncology-Kinston"

Disease/Site: Breast
Protocol Number: ECOG-ACRIN EA1131
Phase:

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer Vidant Oncology-Kinston"

Disease/Site: Breast
Protocol Number: NRG-BR003
Phase: III

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A randomized, double-blind, parallel group, placebo-controlled multi-centre phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA ½ mutations with high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy Vidant Oncology-Kinston"

Disease/Site: Breast
Protocol Number: NSABP B55/BIG 6-13
Phase:

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer Vidant Oncology-Kinston"

Disease/Site: Breast
Protocol Number: "SWOG S1416"
Phase: III

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy Vidant Oncology-Kinston"

Disease/Site: Breast
Protocol Number: S1418/BR006
Phase: III

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304. Vidant Oncology-Kinston"

Disease/Site: CLL
Protocol Number: "TG Therapeutics UTX-TGR 204 (UNITY - CLL)"
Phase:

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair Vidant Oncology-Kinston"

Disease/Site: Colon
Protocol Number: Alliance A021502
Phase: II

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification Vidant Oncology-Kinston"

Disease/Site: Colorectal
Protocol Number: "SWOG S1613"
Phase: II

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"Randomized phase II/III trial of surgery and postoperative radiation delivered with concurrent cisplatin versus docetaxel versus docetaxel and cetuximab for high-risk squamous cell cancer of the head and neck Vidant Oncology-Kinston"

Disease/Site: Head/Neck
Protocol Number: "RTOG 1216"
Phase: II/III

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices Vidant Oncology-Kinston"

Disease/Site: Hodgkin Lymphoma
Protocol Number: CA209-644
Phase:

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer Vidant Oncology-Kinston"

Disease/Site: Lung
Protocol Number: Alliance A0221504
Phase:

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST – Genotype Screening component) Vidant Oncology-Kinston"

Disease/Site: Lung
Protocol Number: Alliance A151216 (ALCHEMIST)
Phase: NA

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completed Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) Vidant Oncology-Kinston"

Disease/Site: Lung
Protocol Number: Alliance A081105 (ALCHEMIST)
Phase: III

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A Phase III Double blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein Vidant Oncology-Kinston"

Disease/Site: Lung
Protocol Number: ECOG-ACRIN E4512 (ALCHEMIST)
Phase: III

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"Adjuvant Nivolumab in Resected Lung Cancers (ANVIL): A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers Vidant Oncology-Kinston"

Disease/Site: Lung
Protocol Number: ECOG-ACRIN EA5142 (ALCHEMIST)
Phase: III

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients with Previously Treated Non-Squamous NSCLC Vidant Oncology-Kinston"

Disease/Site: Lung
Protocol Number: ECOG-ACRIN EA5152
Phase: II

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"Phase II/III biomarker-driven master protocol for previously treated squamous cell lung cancer Vidant Oncology-Kinston"

Disease/Site: Lung
Protocol Number: "SWOG S1400"
Phase: II/III

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A Phase II Study of MEDI4736 (Durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated ANTI-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer Vidant Oncology-Kinston"

Disease/Site: Lung
Protocol Number: "SWOG S1400F"
Phase: II

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer Vidant Oncology-Kinston"

Disease/Site: Lung
Protocol Number: SWOG S1400K
Phase: II/III

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with Pembrolizumab in Patients with Non-Small Cell Lung Cancer Vidant Oncology-Kinston"

Disease/Site: Lung
Protocol Number: "Tesaro 300-02-001"
Phase: II

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"Randomized phase II/III study of nivolumab plus ipilimumab plus sargramostim versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma Vidant Oncology-Kinston"

Disease/Site: Melanoma
Protocol Number: ECOG-ACRIN EA6141
Phase: II/III

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A randomized phase III trial of dabrafenib + trametinib followed by ipilimumab + nivolumab at progression vs. ipilimumab + nivolumab followed by dabrafenib + trametinib at progression in patients with advanced BRAFV600 mutant melanoma Vidant Oncology-Kinston"

Disease/Site: Melanoma
Protocol Number: ECOG-ACRIN EA6134
Phase: III

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E/K mutant melanoma Vidant Oncology-Kinston"

Disease/Site: Melanoma
Protocol Number: "SWOG S1320"
Phase: II

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A randomized phase I/II study of optimal induction therapy of bortezomib, dexamethasone and lenalidomide with or without elotuzumab for newly diagnosed high risk multiple myeloma (HRMM) Vidant Oncology-Kinston"

Disease/Site: Multiple Myeloma
Protocol Number: "SWOG S1211"
Phase: I/II

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A phase 3b randomized study of lenalidomide (CC-5013) plus rituximab maintenance therapy followed by lenalidomide single-agent maintenance versus rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma Vidant Oncology-Kinston"

Disease/Site: Non-Hodgkins Lymphoma
Protocol Number: CC-5013-NHL-008
Phase: IIIB

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non- Hodgkin’s Lymphoma. Vidant Oncology-Kinston"

Disease/Site: Non-Hodgkins Lymphoma
Protocol Number: "TG Therapeutics UTX-TGR 205 (UNITY - NHL)"
Phase: IIb

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A phase IIR and a phase III trial evaluating both erlotinib (Ph IIR) and chemoradiation (Ph III) as adjuvant treatment for patients with resected head of pancreas adenocarcinoma Vidant Oncology-Kinston"

Disease/Site: Pancreatic
Protocol Number: "RTOG 0818"
Phase: II/III

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A randomized phase II study of perioperative mFOLFIRINOX versus gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma Vidant Oncology-Kinston"

Disease/Site: Pancreatic
Protocol Number: "SWOG S1505"
Phase: II

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5-FU/FA and Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in patients with first-line metastatic colorectal cancer Vidant Oncology-Kinston"

Disease/Site: "Peripheral Neuropathy (PND IRB APP)"
Protocol Number: "39815 (POLAR-M)"
Phase: III

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial Vidant Oncology-Kinston"

Disease/Site: Prostate
Protocol Number: "ECOG-ACRIN EA8153"
Phase: NA

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A phase II/III trial of neoadjuvant FOLFOX, with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision Vidant Oncology-Kinston"

Disease/Site: Rectal
Protocol Number: "NRG N0148"
Phase: II/III

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy Vidant Oncology-Kinston"

Disease/Site: Renal Cell
Protocol Number: ECOG-ACRIN EA8142
Phase: III

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"Randomized phase II study of nivolumab with or without ipilimumab in patients with metastatic or unresectable sarcoma Vidant Oncology-Kinston"

Disease/Site: Sarcoma
Protocol Number: Alliance A091401
Phase: II

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

"Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial Vidant Oncology-Kinston"

Disease/Site: VTE
Protocol Number: AFT-28 CANVAS
Phase: NA

PI/Coordinator: "Misbah Qadir/ JoAnne Moye"
Open Date:
Contact Information: 252-559-2201

More information on Cancer Programs & Support